The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells
View ORCID ProfileAnthony Lemarié, Vincent Lubrano, View ORCID ProfileCaroline Delmas, Amélie Lusque, View ORCID ProfileJuan-Pablo Cerapio, View ORCID ProfileMarion Perrier, View ORCID ProfileAurore Siegfried, Florent Arnauduc, Yvan Nicaise, View ORCID ProfilePerrine Dahan, View ORCID ProfileThomas Filleron, Muriel Mounier, View ORCID ProfileChristine Toulas, Elizabeth Cohen-Jonathan Moyal
doi: https://doi.org/10.1101/2023.01.18.23284651
Anthony Lemarié
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
2UFR santé, Université de Toulouse III-Paul Sabatier, Toulouse, France
Vincent Lubrano
3TONIC, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Toulouse Neuro Imaging Center, Toulouse, France
4CHU de Toulouse, Neurosurgery department, Toulouse, France
Caroline Delmas
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
Amélie Lusque
5Institut Claudius Regaud, IUCT-Oncopole, Biostatistics and Health Data Science Unit, Toulouse, France
Juan-Pablo Cerapio
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
Marion Perrier
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
Aurore Siegfried
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
6CHU de Toulouse, Anatomopathology department, Toulouse, France
Florent Arnauduc
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
2UFR santé, Université de Toulouse III-Paul Sabatier, Toulouse, France
Yvan Nicaise
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
2UFR santé, Université de Toulouse III-Paul Sabatier, Toulouse, France
Perrine Dahan
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
Thomas Filleron
5Institut Claudius Regaud, IUCT-Oncopole, Biostatistics and Health Data Science Unit, Toulouse, France
Muriel Mounier
5Institut Claudius Regaud, IUCT-Oncopole, Biostatistics and Health Data Science Unit, Toulouse, France
Christine Toulas
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
7Institut Claudius Regaud, IUCT-Oncopole, Cancer Biology department, Molecular oncology division, Toulouse, France
Elizabeth Cohen-Jonathan Moyal
1CRCT, Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
2UFR santé, Université de Toulouse III-Paul Sabatier, Toulouse, France
8Institut Claudius Regaud, IUCT-Oncopole, Radiation Oncology department, Toulouse, France
Data Availability
All data produced in the present work are contained in the manuscript, with the exception of the raw RNAseq data, which will be publicly available upon acceptance for publication.
Posted January 19, 2023.
The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells
Anthony Lemarié, Vincent Lubrano, Caroline Delmas, Amélie Lusque, Juan-Pablo Cerapio, Marion Perrier, Aurore Siegfried, Florent Arnauduc, Yvan Nicaise, Perrine Dahan, Thomas Filleron, Muriel Mounier, Christine Toulas, Elizabeth Cohen-Jonathan Moyal
medRxiv 2023.01.18.23284651; doi: https://doi.org/10.1101/2023.01.18.23284651
The STEMRI trial: magnetic resonance spectroscopy imaging can define tumor areas enriched in glioblastoma-initiating cells
Anthony Lemarié, Vincent Lubrano, Caroline Delmas, Amélie Lusque, Juan-Pablo Cerapio, Marion Perrier, Aurore Siegfried, Florent Arnauduc, Yvan Nicaise, Perrine Dahan, Thomas Filleron, Muriel Mounier, Christine Toulas, Elizabeth Cohen-Jonathan Moyal
medRxiv 2023.01.18.23284651; doi: https://doi.org/10.1101/2023.01.18.23284651
Subject Area
Subject Areas
- Addiction Medicine (322)
- Allergy and Immunology (626)
- Anesthesia (162)
- Cardiovascular Medicine (2351)
- Dermatology (206)
- Emergency Medicine (377)
- Epidemiology (11734)
- Forensic Medicine (10)
- Gastroenterology (697)
- Genetic and Genomic Medicine (3710)
- Geriatric Medicine (347)
- Health Economics (632)
- Health Informatics (2383)
- Health Policy (928)
- Hematology (340)
- HIV/AIDS (774)
- Medical Education (364)
- Medical Ethics (104)
- Nephrology (396)
- Neurology (3468)
- Nursing (197)
- Nutrition (520)
- Oncology (1808)
- Ophthalmology (534)
- Orthopedics (218)
- Otolaryngology (286)
- Pain Medicine (231)
- Palliative Medicine (66)
- Pathology (445)
- Pediatrics (1025)
- Primary Care Research (417)
- Public and Global Health (6114)
- Radiology and Imaging (1267)
- Respiratory Medicine (822)
- Rheumatology (379)
- Sports Medicine (320)
- Surgery (398)
- Toxicology (50)
- Transplantation (171)
- Urology (145)